Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

Studies show Zepbound can improve the condition by reducing body weight, according to the FDA. The move comes as weight-loss medications have garnered immense national attention and ignited a ...

The FDA approval for sleep apnea is based on two ... a mainstay of treatment that helps keep the airway open. Treatment with Zepbound, whose generic name is tirzepatide, led to improvements ...